# Gene Targeting & Transgenic Mouse

> **NIH NIH P30** · ALBERT EINSTEIN COLLEGE OF MEDICINE · 2021 · $146,353

## Abstract

PROJECT SUMMARY – GENE TARGETING AND TRANSGENIC FACILITY
The Gene Targeting and Transgenic facility was founded over 28 years ago to assist AECC researchers in
the generation of genetically modified mouse models of human disease. Initially, the Gene Targeting and
Transgenic components operated as independent Shared Resources, however, following relocation to state-of-
the-art laboratory space in the Price Center, the facilities were merged into a single Gene Targeting and
Transgenic Shared Resource (GT&TF) In addition, a Gene Modification Service was implemented and
integrated with the Facility to provide a complete service for the rapid and cost efficient generation of
genetically modified mouse lines to all AECC investigators. The Transgenic component of the facility continues
to generate, with high efficiency (~100% success rate), transgenic mouse strains through the introduction of
DNA sequences, such as regular plasmid vectors or BAC clones, into the germ line by pronuclear injection or
by lentivirus infection of fertilized oocytes. For each project, the facility supervisor consults with individual
investigators and advises on transgene construct design, as well as making plasmids and sequence cassettes
available to ensure suitability for expression in the mouse. The Gene Targeting component provided services
for modification of the mouse genome through the use of CRISPR/Cas9 gene editing which was established
during the current funding period. Although the vast majority of gene targeting projects are now conducted by
CRISPR/Cas9, the facility continues to provide conventional gene targeting in embryonic stem (ES) cells and
blastocyst injections upon request. Gene Targeting services include the generation of conventional knockout
mouse lines, knock-in mouse lines and mouse lines with conditional alleles for the temporal and spatial
ablation of genes. The facility has a high success rate (>95%) for obtaining gene targeted mouse lines. Finally,
the services of the facility include the design and generation of simple and complex gene targeting vectors,
electroporation and screening of embryonic stem cell lines as well as human and mouse cancer cell lines and
the generation of chimeric mice by blastocyst injection. In addition, the facility offers mouse reproductive
services for cryopreservation and re-derivation of transgenic and gene-targeted mouse lines as well as IVF
services. Typically 25-30 investigators use this service each year with approximately 200 founder mice
generated per year.

## Key facts

- **NIH application ID:** 10228635
- **Project number:** 5P30CA013330-49
- **Recipient organization:** ALBERT EINSTEIN COLLEGE OF MEDICINE
- **Principal Investigator:** WINFRIED EDELMANN
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $146,353
- **Award type:** 5
- **Project period:** 1997-06-01 → 2023-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10228635

## Citation

> US National Institutes of Health, RePORTER application 10228635, Gene Targeting & Transgenic Mouse (5P30CA013330-49). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10228635. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*